Intra-neuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases

Journal of Clinical Investigation

Volumn 121, Issue 8, 2011, Pages 3320-3330

  Goldstein, David S ^a   Holmes, Courtney ^a   Kopin, Irwin J ^a   Sharabi, Yehonatan ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 6 FLUORODOPAMINE F 18; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; NORADRENALIN; NORADRENALIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; CATECHOLAMINE UPTAKE; CELL VACUOLE; CONTROLLED STUDY; CYTOSOL; DEAMINATION; FEMALE; HEART MUSCLE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; NERVE CELL; NEUROIMAGING; NORADRENERGIC NERVE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; PURE AUTONOMIC FAILURE; SHY DRAGER SYNDROME; SYMPATHETIC NERVE; UNIFIED PARKINSON DISEASE RATING SCALE;

3,4-DIHYDROXYPHENYLACETIC ACID; AGED; CATECHOLAMINES; CYTOSOL; DESIPRAMINE; DOPAMINE; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; LEWY BODY DISEASE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MYOCARDIUM; NEURONS;

EID: 79960983489     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45803     Document Type: Article

References (57)

1. Kaufmann H, Goldstein DS. Dysautonomia in Parkinson disease. In Aminoff MJ, Boller F, Swaab DF, eds. Handbook of Clinical Neurology. New York, New York, USA: Elsevier; 2007:343-363.
2. Amino T, Orimo S, Takahashi A, Uchihara T, Mizusawa H. Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 2005;15(1):29-34. (Pubitemid 40224064)
3. Goldstein DS, Orimo S. Cardiac sympathetic neuroimaging: summary of the First International Symposium. Clin Auton Res. 2009;19(3):137-148.
4. Goldstein DS. Cardiac denervation in patients with Parkinson disease. Cleve. Clin. J. Med. 2007;74(suppl 1):S91-S94.
5. Goldstein DS, et al. Cardiac sympathetic denervation preceding motor signs in Parkinson disease. Clin Auton Res. 2007;17(2):118-121. (Pubitemid 46669418)
6. Dickson DW, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol. 2008;115(4):437-444.
7. Sossi V, de la Fuente-Fernandez R, Schulzer M, Troiano AR, Ruth TJ, Stoessl AJ. Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study. Ann Neurol. 2007;62(5):468-474. (Pubitemid 350308771)
8. Sossi V, et al. Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data. J Cereb Blood Flow Metab. 2002;22(2):232-239. (Pubitemid 34135654)
9. Goldstein DS, Holmes C. Metabolic fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in humans. Clin Exp Hypertens. 1997;19(1-2):155-161. (Pubitemid 27084533)
10. Goldstein DS, Katzper M, Linares OA, Kopin IJ. Kinetic model for the fate of the sympathoneural imaging agent 6-[18F]fluorodopamine in the human heart: a novel means to assess cardiac sympathetic neuronal function. Naunyn-Schmiedebergs Arch Pharmacol. 2002;365(1):38-49. (Pubitemid 34045238)
11. Chang PC, Szemeredi K, Grossman E, Kopin IJ, Goldstein DS. Fate of tritiated 6-fluorodopamine in rats: a false neurotransmitter for positron emission tomographic imaging of sympathetic innervation and function. J Pharmacol Exp Ther. 1990;255(2):809-817.
12. Eisenhofer G, et al. Neuronal uptake and metabolism of 2- and 6-fluorodopamine: false neurotransmitters for positron emission tomographic imaging of sympathetically innervated tissues. J Pharmacol Exp Ther. 1989;248(1):419-427. (Pubitemid 19063522)
13. Goldstein DS, et al. Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine. J Hypertens. 1991;9(5):417-423.
14. Kaufmann H, Hague K, Perl D. Accumulation of alpha-synuclein in autonomic nerves in pure autonomic failure. Neurology. 2001;56(7):980-981. (Pubitemid 32290824)
15. Tipre DN, Goldstein DS. Cardiac and extra-cardiac sympathetic denervation in Parkinson disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med. 2005;46(11):1775-1781. (Pubitemid 46196637)
16. Shy GM, Drager GA. A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol. 1960;2:511-527.
17. Wakabayashi K, Yoshimoto M, Tsuji S, Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett. 1998;249(2-3):180-182. (Pubitemid 28331545)
18. Goldstein DS, Holmes C, Sharabi Y, Brentzel S, Eisenhofer G. Plasma levels of catechols and metanephrines in neurogenic orthostatic hypotension. Neurology. 2003;60(8):1327-1332. (Pubitemid 36460990)
19. Goldstein DS, Eisenhofer G, Stull R, Folio CJ, Keiser HR, Kopin IJ. Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest. 1988;81(1):213-222.
20. Orimo S, et al. Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry. 2002;73(6):776-777. (Pubitemid 35448873)
21. Hague K, Lento P, Morgello S, Caro S, Kaufmann H. The distribution of Lewy bodies in pure autonomic failure: autopsy findings and review of the literature. Acta Neuropathol. 1997;94(2):192-196. (Pubitemid 27338509)
22. Goldstein DS, et al. Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol. 1989;26(4):558-563. (Pubitemid 19247233)
23. Mosharov EV, et al. Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J Neurosci. 2006;26(36):9304-9311. (Pubitemid 44359856)
24. Guo JT, Chen AQ, Kong Q, Zhu H, Ma CM, Qin C. Inhibition of vesicular monoamine transporter-2 activity in alpha-synuclein stably transfected SH-SY5Y cells. Cell Mol Neurobiol. 2008;28(1):35-47.
25. Volles MJ, Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. Biochemistry. 2002;41(14):4595-4602. (Pubitemid 34275660)
26. Okamura N, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010;51(2):223-228.
27. Sala G, et al. Vesicular monoamine transporter 2 mRNA levels are reduced in platelets from patients with Parkinson's disease. J Neural Transm. 2010;117(9):1093-1098.
28. Hardwick JC, Ehrlich YH, Hendley ED. Extracellular ATP stimulates norepinephrine uptake in PC12 cells. J Neurochem. 1989;53(5):1512-1518. (Pubitemid 19268730)
29. Volz TJ, Hanson GR, Fleckenstein AE. Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetry. J Neurosci Methods. 2006;155(1):109-115. (Pubitemid 43870124)
30. Xie T, Ho SL, Li LS, Ma OC. G/A1947 polymorphism in catechol-O- methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997;12(3):426-427. (Pubitemid 27216145)
31. Goldstein DS, et al. Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension. 2005;46(6):1333-1339. (Pubitemid 43189732)
32. Li ST, Holmes C, Kopin IJ, Goldstein DS. Aging-related changes in cardiac sympathetic function in humans, assessed by 6-18F-fluorodopamine PET scanning. J Nucl Med. 2003;44(1):1599-1603. (Pubitemid 39663330)
33. Berman SB, Hastings TG. Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J Neurochem. 1999;73(3):1127-1137. (Pubitemid 29395471)
34. Creveling CR. The Role of Catechol Quinone Species in Cellular Toxicity. Johnson City, Tennessee, USA: FP Graham Publishing Co.; 2000.
35. Burke WJ, et al. Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases. Neurotoxicology. 2004;25(1-2):101-115. (Pubitemid 38044173)
36. Hermida-Ameijeiras A, Mendez-Alvarez E, Sanchez-Iglesias S, Sanmartin-Suarez C, Soto-Otero R. Autoxidation and MAO-mediated metabolism of dopamine as a potential cause of oxidative stress: role of ferrous and ferric ions. Neurochem Int. 2004;45(1):103-116. (Pubitemid 38479570)
37. Mosharov EV, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron. 2009;62(2):218-229.
38. Burke WJ, et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 2008;115(2):193-203.
39. Rees JN, Florang VR, Anderson DG, Doorn JA. Lipid peroxidation products inhibit dopamine catabolism yielding aberrant levels of a reactive intermediate. Chem Res Toxicol. 2007;20(10):1536-1542. (Pubitemid 350057224)
40. Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA. Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem Res Toxicol. 2009;22(5):835-841.
41. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC. Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol. 2011;18(5):703-710.
42. Wakade AR. A comparison of rates of depletion and recovery of noradrenaline stores of peripheral and central noradrenergic neurones after reserpine administration: importance of neuronal activity. Br J Pharmacol. 1980;68(1):93-98. (Pubitemid 10131893)
43. Carlsson A. Biochemical and pharmacological aspects of Parkinsonism. Acta Neurol Scand Suppl. 1972;51:11-42.
44. Mitchell IJ, et al. Glutamate-induced apoptosis results in a loss of striatal neurons in the parkinsonian rat. Neuroscience. 1994;63(1):1-5. (Pubitemid 24333947)
45. Taylor TN, et al. Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity. J Neurosci. 2009;29(25):8103-8113.
46. Gainetdinov RR, et al. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem. 1998;70(5):1973-1978. (Pubitemid 28207819)
47. Speciale SG, Liang CL, Sonsalla PK, Edwards RH, German DC. The neurotoxin 1-methyl-4-phenyl-pyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience. 1998;84(4):1177-1185. (Pubitemid 28157032)
48. Sun M, et al. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease. Hum Gene Ther. 2004;15(12):1177-1196. (Pubitemid 40052431)
49. Watabe M, Nakaki T. Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol Pharmacol. 2008;74(4):933-940.
50. Sai Y, Wu Q, Le W, Ye F, Li Y, Dong Z. Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Toxicol In Vitro. 2008;22(6):1461-1468.
51. Lamensdorf I, Eisenhofer G, Harvey-White J, Hayakawa Y, Kirk K, Kopin IJ. Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde. J Neurosci Res. 2000;60(4):552-558. (Pubitemid 30252918)
52. Liu HQ, Zhu XZ, Weng EQ. Intracellular dopamine oxidation mediates rotenone-induced apoptosis in PC12 cells. Acta Pharmacol Sin. 2005;26(1):17-26.
53. Kaufmann H. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure and multiple system atrophy. Clin Auton Res. 1996;6(2):125-126.
54. Goldstein DS, Tack C. Noninvasive detection of sympathetic neurocirculatory failure. Clin Auton Res. 2000;10(5):285-291. (Pubitemid 32066010)
55. Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in primary orthostatic hypotension. N Engl J Med. 1977;296(6):293-297. (Pubitemid 8047240)
56. Holmes C, Eisenhofer G, Goldstein DS. Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Biomed Appl. 1994;653(2):131-138. (Pubitemid 24085051)
57. Goldstein DS, Sewell L, Sharabi Y. Autonomic dysfunction in PD: a window to early detection? [published online ahead of print April 27, 2011]. J Neurol Sci. doi:10.1016/j.jns.2011.04.011.